Saturday 17 October 2026
Export KRRO’s income statement to Excel — free account
Korro Bio, Inc.
KRRO Healthcare Biotechnology
Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.53
0.78
−8.38%
Follow KRRO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
30.98 | 11.77 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(26.18) | (4.25) | — | — | |
P/B ratio |
4.54 | 1.46 | — | — | |
Price to Tangible BV |
4.54 | 1.46 | — | — | |
EV/Sales |
25.88 | 2.88 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(5.50) | (0.23) | — | — | |
EV/FCF |
(5.35) | (0.23) | — | — | |
Quick Ratio |
6.37 | 6.38 | 7.71 | 9.11 | |
Current Ratio |
6.71 | 6.90 | 8.13 | 9.55 | |
Net Debt/EBITDA |
5.11 | 1.51 | 5.68 | 5.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.04 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.35 | 0.82 | 0.90 | |
Capex/Depreciation |
(0.15) | (0.13) | (0.05) | (0.10) | |
Research and Development Expense of Revenue |
1,267.89% | 919.58% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
596.97% | 505.19% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
167.43% | 160.29% | 0.00% | 0.00% | |
Graham Net Nets |
0.08 | 0.27 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(19.65%) | (155.68%) | — | — | |
Free Cash Flow Yield |
(15.62%) | (105.08%) | — | — | |
Revenue per Share |
0.12 | 0.14 | 0.00 | 0.00 | |
Operating CF per Share |
(1.83) | (1.88) | (1.39) | (0.96) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.85) | (1.89) | (1.39) | (0.97) | |
Cash per Share |
9.85 | 8.00 | 9.83 | 6.53 | |
Shareholders Equity per Share |
10.54 | 5.48 | 10.31 | 5.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.54 | 5.48 | 10.31 | 5.86 | |
Free Cash Flow |
(17.35) | (17.79) | (16.09) | (17.03) | |
Working Capital |
83.59 | 70.44 | 105.38 | 108.00 | |
Capital Expenditures |
(0.17) | (0.08) | (0.02) | (0.04) | |
Net Current Asset Value |
35.71 | 20.31 | 56.17 | 60.41 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.16 | 0.07 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
5.41 | 1.33 | — | — | |
Average Payables |
4.13 | 2.82 | 3.07 | 4.38 | |
Average Assets |
202.55 | 169.87 | 192.91 | 171.94 | |
Average Common Equity |
139.33 | 105.93 | 129.30 | 109.16 |
Columns are period end dates